bioRxiv Science⌕ Search

Biology subjects

Mghabghab, R.

Publications and source records attributed to Mghabghab, R..

2 recordsLinked to original sources

Global warming drives the evolutionary rate of H1N1 and H3N2 influenza viruses

The haemagglutinin (HA) and neuraminidase (NA) genes of seasonal influenza A evolve under continual immune-driven positive selection. To test whether the tempo of selection has changed over time, we mapped branch- and site-specific episodic diversifying selection (MEME) onto Bayesian relaxed-clock time trees for HA and NA in H1N1 and H3N2, across multiple countries and four sequence-subsampling schemes. We dated each selection episode and tested whether episodes accumulated through time after accounting for the growing number of sampled lineages. Positive-selection episodes increased over time in every gene-subtype combination, at about 2-6% per lineage-year, and rose faster for NA than HA. Episodes were concentrated at a small number of codon sites, especially recurrent sites in H3N2 HA that fell within canonical antigenic regions of the HA1 head. This increase was robust to subsampling scheme and time-bin width, and was driven disproportionately by recent lineages. A detrended spatial analysis found no association with latitude or temperature anomalies. Overall, positive selection on influenza surface antigens appears to be intensifying through time, most likely because of immune escape and expanded surveillance rather than climate warming.

evolutionary biology↗

NTBC dosing and outcomes in hereditary tyrosinemia type 1: insights from a representative human model and 99 patients

Hereditary tyrosinemia type 1 (HT1) is a rare and severe metabolic liver disorder caused by fumarylacetoacetate hydrolase (FAH) deficiency. The optimal dose and long-term effects of the only available treatment, nitisinone (NTBC), remain unclear due to the absence of clinical trial data. Here, we generated a representative human in vitro model of HT1 using iPSC-derived hepatocytes, which faithfully recapitulated key disease features. We investigated the mechanisms of FAH deficiency-induced hepatocellular injury and evaluated the effects of NTBC treatment. We confirmed treatment efficacy and identified 50 {micro}mol/L as the minimal effective NTBC concentration to prevent cellular damage. This protective dose was subsequently validated in a large cohort of 99 HT1 patients, providing compelling evidence for establishing minimal therapeutic NTBC levels. Notably, approximately 10% of disease-associated genes, many implicated in hepatocellular carcinoma, remained dysregulated despite treatment, raising concerns that NTBC may not fully eliminate long-term oncogenic risk.

genetics↗